PUBLISHER: Grand View Research | PRODUCT CODE: 1842339
PUBLISHER: Grand View Research | PRODUCT CODE: 1842339
The global thyroid cancer diagnostics market size was estimated at USD 3.07 billion in 2024 and is projected to reach USD 5.03 billion by 2033, growing at a CAGR of 5.86% from 2025 to 2033. This growth is attributed to the growing incidence of thyroid cancer, growing awareness of early screening programs, and significant technological advancements in diagnostic tools such as imaging modalities and molecular testing.
In addition, increased healthcare spending, favorable reimbursement policies, and a shift toward personalized medicine. Furthermore, the growing aging population, improved healthcare infrastructure, and ongoing research and development efforts further support market expansion, enabling earlier and more accurate detection and management of thyroid cancer.
Thyroid cancer diagnostics encompass a broad range of tests and procedures, including imaging, biopsies, blood tests, and molecular profiling used to detect and characterize thyroid cancer, guiding clinical decisions and personalized treatment. The global market for these diagnostics is expanding rapidly, largely due to the increasing number of thyroid cancer patients. This rise in cases has heightened the demand for early detection and effective screening tools, as healthcare providers prioritize proactive identification to improve outcomes. According to the American Cancer Society, about 44,020 new cases of thyroid cancer are expected to be diagnosed in the U.S. in 2025. Approximately 31,350 cases occur in women and 12,670 in men. Thyroid cancer is notably more common in women and is often diagnosed at a younger age compared to many other cancers.
A significant driver of this market is technological advancement. For instance, in May 2024, GE Healthcare introduced Revolution RT, an advanced radiation therapy computed tomography (CT) solution. This innovative system is designed to enhance imaging accuracy and streamline simulation workflows, supporting a more personalized and seamless oncology care experience. Revolution RT incorporates AI-driven technologies and updated software platforms, enabling clinicians to achieve precise tumor targeting and more efficient care pathways.
In addition, the adoption of telemedicine and digital health platforms has further expanded access to thyroid cancer diagnostics, especially for individuals in remote or underserved areas. Through virtual consultations, patients can receive early screening recommendations and follow-up care, ensuring timely intervention regardless of geographic barriers.
Moreover, the growing prevalence of genetic testing for hereditary risk factors is creating new opportunities in the market. Advanced genomic panels can identify mutations linked to thyroid tumors, aiding in more accurate diagnosis and personalized treatment strategies. Collectively, these factors, including the rising incidence of thyroid cancer, cutting-edge technology like Revolution RT, the shift toward personalized medicine, digital health accessibility, and expanded genetic testing, are driving robust growth in the thyroid cancer diagnostics industry, leading to earlier detection and improved patient care.
Global Thyroid Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global thyroid cancer diagnostics market report based on cancer type, technique, end use, and region.